Cellistic (iPSC-focused cell therapy process development & manufacturing unit of NCardia)

https://www.cellistic.com

LinkedIn: https://www.linkedin.com/company/cellistic

Launched in April 2022, Cellistic™ specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia's scientific and technical knowledge and experience, Cellistic™ possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale. *

	Start	2022-04-01 established
	Group	Kiniciti Bio (WCAS invesment platform) (Group)
	Industry	contract manufacturing (BCS)
	Industry 2	iPSC technology (induced pluripotent stem cell technology)

	Region	Gosselies
	Country	Belgium
	Street	47 Rue Adrienne Bolland
	City	6041 Gosselies
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Quell Therapeutics Ltd.. (4/27/22). "Press Release: Quell Therapeutics and Cellistic Enter a Strategic Collaboration to Develop an iPSC-derived Allogeneic T-regulatory (Treg) Cell Therapy Platform". London & Gosselies.

		Record changed: 2024-02-12